













Agenda – COMPREHENSIVE GENE PROFILING, MOLECULAR TUMOR BOARD (MTB) AND ARTIFICIAL INTELLIGENCE IN THE DIAGNOSIS AND TREATMENT OF PATIENTS WITH RARE ADULT CANCERS

Venue: Medisiina D and conference room Lauren 2, Kiinamyllynkatu 10, Turku, Finland, and Sokos Hotel Kupittaa, Joukahaisenkatu 6, Turku

Date: September the 29th-30th, 2022

Organizer: FICAN WEST Cancer Centre and Turku University Hospital (TYKS) and ERN-EURACAN and GENTURIS

All times are in EEST (Eastern European Summer Time)

Day 1 - Thursday, September the 29th

Time	Title, Speaker and Affiliation	Session name/Topic
9.00-9.10	Opening words by Pia Vihi <mark>nen,</mark> Associate professor, FICAN West Cancer Centre	
9.10-9.50	Cancer research with the help of real-world patient data, artificial intelligence, and deep-learning methods. Pekka Ruusuvuori, Prof., Turku Institute of Biomedicine, University of Turku	Session 1. Artificial intelligence and advances in
9.50-10.20	Biobank studies helping in treatment of patients with rare cancers. Merja Perälä, PhD, Associate professor, Auria Biobank and Eva-Maria Talvitie, MD, Turku University Hospital	pathological diagnostics Chairs: Prof. Markku Kallajoki and Dr. Katri Orte, MD, PhD
10.2011.00	iCAN flagship in Finland. Tomi Mäkelä, Prof., iCAN – Digital Precision Cancer Medicine Flagship, Helsinki Institute of Life Science, University of Helsinki	
11.00-12.00	Lunch	
12.00-12.45	Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features. Edwin Cuppen, Prof., Hartwig	Session 2. Biological basics and novel technics in comprehensive gene profiling










VARSINAIS-SUOMEN SAIRAANHOITOPIIRI SATASARA ARAKUNNAN SAIRAANHOITOPIIRI





	Medical Foundation, Amsterdam,	Chairs: Prof. Klaus
	Netherlands	Elenius and Associate
12.45-13.30	Crowd validation of a national	Prof. Maria Sundvall
12.45-15.50	broad custom DNA/RNA-capture	Troi: Mana Sanavan
	panel for precision oncology in	
	Sweden. Johan Botling, Associate	
	Professor of Pathology, Department	
	of Immunology Genetics and	
	Pathology Rudbeck Laboratory,	
	Uppsala University Hospital, Sweden	
13.30-14.00	Artificial intelligence for image-	
13.30-14.00	based melanoma diagnosis. Nina	
	Linder, MD, Associate Prof., Institute	
	for Molecular Medicine Finland and	
14.00-14.30	University of Helsinki CIC-rearranged sarcoma and	
14.00-14.30	diagnostic challenges. Patient cases.	
	Jenni Tuominen, MSc and Katri Orte,	
	MD, PhD, Turku University Hospital	
14.30-15.00	and applicants Coffee break	
15.00-15.30	Possibilities and limitations of clinical	
13.00-13.30	liquid biopsy testing. Niels	
	Pallisgaard, Prof. Sjællands	
	Universitetshospital, Roskilde,	
	Denmark	
15.30-16.00	Usefulness of liquid biopsy in	/
13.30-10.00	treatment and follow-up of cancer	Session 3. Novel
	patients. Juha Kononen, Chief	technologies in
	Clinical Director, Docrates Cancer	patient sampling and
	Center, Helsinki	sample analysis
16.00-16.45	2 patient cases presented by	Chairs: Associate Prof.
10.00 10.43	applicants (30 min) and discussion	Veli Kairisto and Prof.
16.45-17.15	Precision oncology using ex vivo	Panu Jaakkola
10.10 17.10	technology: a step towards	
	individualized cancer care? Noora	
	Nykänen, MSc, Specializing Medical	
	Cell Biologist, University of Jyväskylä,	
	Finland	
18.00	End of the day 1	
20.00	Dinner at Restaurant Grädda	
	(Invited participants)	




















Day 2 - Friday, September the 30th.

Time	Speaker and Affiliation	Session name/Topic
9.00-9.45	Functional precision medicine. Olli	
7100 7110	Kallioniemi, Prof., SciLifeLab &	
	Karolinska Institutet and FIMM,	
	University of Helsinki	
9.45-10.30	Lessons learned from Drug	
7110 10100	rediscovery program trials (DRUP)	
	and precision medicine schemes	
	what next? Ilse Spiekman, DRUP	
	study coordinator, Netherlands	
	Cancer Institute, Amsterdam	
	Netherlands	Session 4. Bringing
10.30-10.50	Arrangement and function of MTB at	precision medicine to
	FICAN West Cancer Centre and	patients
	importance of Finprove study in	Chairs: Eva-Maria
	Finland. Erika Alanne, MD, PhD	Talvitie and Katri Orte
	FICAN West Cancer Centre and	
	Turku University Hospital	
10.50-11.10	Genetic counselling in patients with	
(virtual)	rare hereditary cancers. Kerry	
	Kingham MS, CGC, Certified	
	Genetic Counselor, Lead, Clinical	
	Assistant Professor of Pediatrics,	
	Cancer Genetics and Genomics,	
	Stanford Cancer Center, USA	
11.10-12.00	Lunch	
12.00-12.30	Experiences with arrangement of a	Session 5. Optimal
	national precision cancer medicine	arrangement of
	implementation initiative. Kjetil	Molecular Tumor
	Tasken, Prof., Institute of Clinical	Boards (MTBs) to
	Medicine, University of Oslo, Norway	support diagnosis of
12.30-12.45	DRUP-like trials in the Nordics: Status	rare cancers and
	of the IMPRESS-Norway study, and	clinical decision-
	how to share data and improve	making
	recruitment of patients. Kjetil Tasken,	Chairs: Dr. Erika
	Prof., Institute of Clinical Medicine,	Alanne and Dr. Maria
	University of Oslo, Norway	Haanpää










SATAKUNNAN SAIRAANHOITOPIIRI





12.45-13.00	Status of Finprove study in Finland. Katriina Peltola, Chief Physician, Clinical Trial Unit, Helsinki Comprehensive Cancer Centre, Helsinki	
13.00-13.15 (virtual)	Status of ProTarget study in Denmark. Kristoffer Staal, Head of Phase I Unit, Departmetnt of Oncology, Centre for Cancer and Organ Diseases, Rigshospitalet, Copenhagen, Denmark	
13.15-13.45	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Janne Lehtiö, Prof., Inflames and Karolinska Institutet, Stockholm, Sweden	
13.45-14.15	Coffee break	
14.00-16.00	Molecular Tumor Board (participants from several institutes) and round table discussion	Session 6. MTB and patient cases Chairs: Dr. Erika Alanne and Dr. Maria Silvoniemi)
16.00	Closing remarks and departure	

Organizing committee: Pia Vihinen, Erika Alanne, Heikki Minn, Klaus Elenius, Veli Kairisto, Maria Sundvall, Maria Silvoniemi, Markku Kallajoki, Katri Orte, Maria Haanpää, Eva-Maria Talvitie, Jenni Tuominen, Mervi Siekkinen, Mervi Toriseva.

